CURX · Curanex Pharmaceuticals Inc
$0.19
0.00 (-2.02%)
At close · Jul 29
Going-concern doubt
— cleared May 14, 2026
The latest filing states the doubt was alleviated.
“In prior years, the Company disclosed conditions that raised substantial doubt about its ability to continue as a going concern. Management has re-evaluated the Company's liquidity and capital resources for the twelve-month period from the date of issuance of these unaudited interim financial statements. While certain conditions and events that previously raised substantial doubt may continue to exist, management's plans, including the successful completion of the Company's initial public offering and related capital raising activities, resulting improvement in liquidity, were determined to mitigate the substantial doubt regarding the Company's ability to continue as a going concern. Accordingly, management concluded that no substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$5.49M
Shares
28.36M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$4.23M
-1068.8%
FY2025
Diluted EPS
-$0.17
-466.7%
FY2025
Operating Cash Flow
-$10.48M
-1787.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 |
|---|---|---|---|
| — | $2.99M | — | |
| $2.04M | $1.25M | $290.39K | |
| $7.28M | $4.24M | $365.06K | |
| -$7.28M | -$4.24M | -$365.06K | |
| — | $8537 | — | |
| -$7.24M | -$4.23M | -$361.51K | |
| USD/shares | — | -$0.17 | -$0.03 |
| USD/shares | — | -$0.17 | -$0.03 |
| shares | — | 25.5M | 13.26M |
| shares | — | 25.5M | 13.26M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Peer median 0.04×
Peer medians compare against the 163 similar-size Biotechnology companies (of 522 listed).